Wells Fargo & Company Issues Positive Forecast for Enovis (NYSE:ENOV) Stock Price

Key Points

• Wells Fargo raised its Enovis price target from $33 to $37 and maintained an “overweight” rating, implying 36.25% upside from the cited share price. Analysts overall rate the stock “Moderate Buy,” with an average target of $39.
• Enovis reported quarterly EPS of $0.88, beating the $0.77 consensus, while revenue of $558.7 million edged estimates and grew 1.8% year over year.
• Company insiders bought 23,293 shares worth about $449,600 over the past three months; separately, Enovis raised its 2026 adjusted EPS guidance and authorized a $200 million share-repurchase program.

Enovis (NYSE:ENOV - Get Free Report) had its price objective boosted by stock analysts at Wells Fargo & Company from $33.00 to $37.00 in a note issued to investors on Friday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Wells Fargo & Company's target price would suggest a potential upside of 36.25% from the company's current price.

Several other analysts have also recently issued reports on ENOV. Needham & Company LLC increased their price objective on Enovis from $34.00 to $38.00 and gave the company a "buy" rating in a research note on Thursday. BMO Capital Markets set a $27.00 target price on Enovis in a report on Tuesday, September 1st. Citigroup reissued a "market outperform" rating on shares of Enovis in a research note on Wednesday, September 2nd. Zacks Research raised Enovis from a "strong sell" rating to a "hold" rating in a research note on Wednesday, July 29th. Finally, Wall Street Zen upgraded Enovis from a "hold" rating to a "buy" rating in a report on Saturday, October 31st. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $39.00.

Enovis Trading Down 5.1%

Shares of ENOV stock opened at $27.16 on Friday. Enovis has a fifty-two week low of $16.70 and a fifty-two week high of $32.41. The company has a 50 day moving average price of $19.86 and a 200 day moving average price of $23.07. The stock has a market capitalization of $1.57 billion, a P/E ratio of -1.40 and a beta of 1.31. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98.

Enovis (NYSE:ENOV - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.77 by $0.11. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. During the same period in the prior year, the business earned $0.75 EPS. The firm's quarterly revenue was up 1.8% on a year-over-year basis. Equities research analysts predict that Enovis will post 3.15 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Oliver Engert acquired 2,660 shares of the company's stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $18.80 per share, with a total value of $50,008.00. Following the transaction, the insider owned 63,898 shares in the company, valued at approximately $1,201,282.40. This trade represents a 4.34% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Damien Mcdonald acquired 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The stock was purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the acquisition, the chief executive officer directly owned 247,077 shares in the company, valued at approximately $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 23,293 shares of company stock worth $449,599. Insiders own 2.90% of the company's stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently bought and sold shares of ENOV. Maryland State Retirement & Pension System acquired a new position in shares of Enovis in the 3rd quarter valued at $238,000. Illinois Municipal Retirement Fund raised its stake in Enovis by 22.4% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 38,366 shares of the company's stock worth $701,000 after acquiring an additional 7,028 shares in the last quarter. Private Management Group Inc. raised its stake in Enovis by 31.3% during the 3rd quarter. Private Management Group Inc. now owns 1,792,429 shares of the company's stock worth $32,748,000 after acquiring an additional 427,347 shares in the last quarter. Fulcrum Asset Management LLP raised its stake in Enovis by 2,739.4% during the 3rd quarter. Fulcrum Asset Management LLP now owns 20,330 shares of the company's stock worth $375,000 after acquiring an additional 19,614 shares in the last quarter. Finally, Villanova Investment Management Co lifted its position in Enovis by 10.2% in the third quarter. Villanova Investment Management Co now owns 148,424 shares of the company's stock valued at $2,712,000 after acquiring an additional 13,740 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis raised its 2026 adjusted EPS guidance to $3.58–$3.79 and authorized a $200 million share-repurchase program, improving its earnings outlook and offering a potential source of share demand. Enovis raises guidance and authorizes buyback
• Positive Sentiment: Third-quarter adjusted EPS was $0.88, above consensus estimates of about $0.76–$0.77 and up from $0.75 a year earlier. Reports highlighted a swing to quarterly profit as a key reason the shares advanced. Enovis climbs on third-quarter profit and sales
• Positive Sentiment: Analyst sentiment also improved: Needham raised its price target to $38 and BTIG lifted its target to $42, both maintaining Buy ratings.
• Neutral Sentiment: Revenue was $558.7 million, slightly above estimates of $557.1 million and 1.8% higher year over year—solid but modest growth. Enovis third-quarter earnings and revenue beat estimates

About Enovis

Enovis Corporation NYSE: ENOV is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company's products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.